SUBSCRIBE
SUBSCRIBE
News   Deals

Drug Data Delay Offers Actelion Ltd. Bid Shield

February 16, 2011 | 
1 min read

ZURICH, Feb 16 (Reuters) - Actelion (ATLN.VX), Europe’s biggest biotech group, could be immune from takeover until the end of the year when data on a key heart and lung drug is due.

Mergers & acquisitions Europe
MORE ON THIS TOPIC
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.
Alzheimer’s disease
GSK Strikes Third Agreement This Week, Leans Further Into Neuro
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Manufacturing
Novo Continues Manufacturing Spending Spree With $400M Denmark Expansion, $200M Plant Purchase
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac